Sai Parenterals Limited is pleased to announce the successful completion of a ₹50 crore equity investment round by a group of marquee investors. The capital will support the company’s growth plans for establishing its international footprint as it pursues its vision to become a global pharmaceutical company.
Samarsh Capital, Vyom Partners, and funds associated with Blue Lotus Capital led the
fundraising round.
Mr. Anil Karusala, Managing Director of Sai Parenterals, remarked:
We are working diligently to build a world-class pharmaceutical company that adheres to the highest global standards and practices. This equity infusion will allow us to acquire high- potential international assets and intellectual property in regulated markets, expand our product portfolio and geographical presence, and enhance our manufacturing capabilities. We are honoured by the confidence of such professional investors in our company’s strategy and future.
Mr. Sandeep Shenoy, Managing Partner of Samarsh Capital, commented:
Our investment in Sai Parenterals reflects our confidence in its solid fundamentals, scalable model, and potential to achieve strong growth in the global pharmaceutical sector. Under the visionary leadership of Anil, we expect Sai Parenterals to emerge as a leader in its segment.
Mr. Prashant Khanchandani of Vyom Partners added:
Sai Parenterals’ leadership has demonstrated a future-ready approach by building a capital- efficient and scalable business. Their success in integrating acquisitions and subsequently expanding internationally in the formulations and CDMO segments is commendable.
Mr. Harikrishnan S, Managing Partner of Blue Lotus Capital stated:
“Our second round of investment reflects our strong conviction in Sai Parenterals’ science-driven culture and scalable manufacturing platform. By partnering with a formidable player in sterile injectables, we aim to accelerate affordable, high-quality healthcare solutions for global markets while delivering sustained value to the investors.”
About The Author
